Screener
Fulgent Genetics, Inc. FLGT Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Equity-based compensation | 9,890 | 10,550 |
| Depreciation and amortization | 6,000 | 5,919 |
| Adjustment for credit losses | 1,189 | 2,075 |
| Noncash lease expense | 352 | 350 |
| Gain on disposal of fixed asset | (9) | (2) |
| Amortization of premium of marketable securities | (890) | (1,658) |
| Deferred taxes | (1,120) | (133) |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s accounts receivable, credit loss expense (reversal)?
- Fulgent Genetics, Inc. (FLGT) reported accounts receivable, credit loss expense (reversal) of $1.19M in Q1 2026.
- How has Fulgent Genetics, Inc.'s accounts receivable, credit loss expense (reversal) changed year-over-year?
- Fulgent Genetics, Inc.'s accounts receivable, credit loss expense (reversal) decreased by 42.7% year-over-year, from $2.08M to $1.19M.
- What is the long-term trend for Fulgent Genetics, Inc.'s accounts receivable, credit loss expense (reversal)?
- Over 2 years (2021 to 2025), Fulgent Genetics, Inc.'s accounts receivable, credit loss expense (reversal) has grown at a -7.5% compound annual growth rate (CAGR), from $8.94M to $7.65M.
Ask your AI about Fulgent Genetics, Inc.'s accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude